{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:01:20Z","timestamp":1776448880614,"version":"3.51.2"},"reference-count":24,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Aggressive pituitary neuroendocrine tumors (PitNETs) present significant morbidity, and multimodal therapies including surgery, radiotherapy, and medications are frequently required. Chemotherapy, particularly temozolomide, is often pursued for tumors that progress despite these treatments. Although peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs is approved for the treatment of well-differentiated gastrointestinal neuroendocrine tumors, its use in aggressive PitNETs is limited. We describe the case of a 65-year-old man who presented with vision changes and hypopituitarism at age 33 secondary to a nonfunctioning gonadotroph PitNET. His initial treatment included a craniotomy followed by radiation therapy. With tumor regrowth, he required transsphenoidal surgeries at age 44 and age 52. At age 56, further tumor regrowth and a positive octreotide scan prompted treatment with long-acting octreotide for 1 year. Given absent tumor response, 12 cycles (4 treatment cycles and 8 maintenance cycles) of PRRT with 177Lutetium-DOTATATE were pursued. This resulted in partial response with significant tumor shrinkage. Notably, there was no tumor regrowth 40 months after treatment discontinuation. This is only the second report on the effectiveness of PRRT in patients with aggressive gonadotroph PitNETs. We also provide an overview of PRRT for PitNETs and describe clinical outcomes previously reported in the literature.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae123","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T06:28:07Z","timestamp":1721024887000},"source":"Crossref","is-referenced-by-count":3,"title":["Treatment of an Aggressive Gonadotroph Pituitary Neuroendocrine Tumor With 177Lutetium DOTATATE Radionuclide Therapy"],"prefix":"10.1210","volume":"2","author":[{"given":"Chaitanya","family":"Gandhi","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta , Edmonton, AB T6G 2G3 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Koumna","sequence":"additional","affiliation":[{"name":"Department of Radiology and Diagnostic Imaging, Cross Cancer Institute , Edmonton, AB T6G 1Z2 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9609-0896","authenticated-orcid":false,"given":"Constance","family":"Chik","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta , Edmonton, AB T6G 2G3 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"issue":"1","key":"2024072410341661800_luae123-B1","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2024072410341661800_luae123-B2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","article-title":"Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment","volume":"108","author":"Burman","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024072410341661800_luae123-B3","doi-asserted-by":"crossref","first-page":"D1","DOI":"10.1530\/EJE-19-0058","article-title":"Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas","volume":"181","author":"Chanson","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2024072410341661800_luae123-B4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11154-020-09556-7","article-title":"The epidemiology of aggressive pituitary tumors (and its challenges)","volume":"21","author":"Dekkers","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"2024072410341661800_luae123-B5","doi-asserted-by":"crossref","first-page":"624686","DOI":"10.3389\/fendo.2021.624686","article-title":"Multimodal non-surgical treatments of aggressive pituitary tumors","volume":"12","author":"Nakano-Tateno","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2024072410341661800_luae123-B6","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1210\/jc.2014-4350","article-title":"Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide","volume":"100","author":"Bengtsson","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024072410341661800_luae123-B7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/ph14090872","article-title":"Peptide receptor radionuclide therapy and primary brain tumors: an overview","volume":"14","author":"Cimini","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"2024072410341661800_luae123-B8","doi-asserted-by":"crossref","first-page":"bvab133","DOI":"10.1210\/jendso\/bvab133","article-title":"Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma","volume":"5","author":"Lin","year":"2021","journal-title":"J Endocr Soc"},{"issue":"3","key":"2024072410341661800_luae123-B9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11102-013-0494-0","article-title":"Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma","volume":"17","author":"Komor","year":"2014","journal-title":"Pituitary"},{"issue":"2","key":"2024072410341661800_luae123-B10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3171\/2015.6.JNS15363","article-title":"Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90 Y-DOTATATE: case report","volume":"125","author":"Walig\u00f3rska-Stachura","year":"2016","journal-title":"J Neurosurg"},{"issue":"5","key":"2024072410341661800_luae123-B11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1530\/EC-19-0065","article-title":"Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Endocr Connect"},{"issue":"Suppl 1","key":"2024072410341661800_luae123-B12","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s11102-011-0373-5","article-title":"First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment","volume":"15","author":"Baldari","year":"2012","journal-title":"Pituitary"},{"issue":"4","key":"2024072410341661800_luae123-B13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.5812\/ijem.4313","article-title":"Diagnosis of MEN-I syndrome on 68Ga-DOTANOC PET-CT and role of peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"10","author":"Kumar Gupta","year":"2012","journal-title":"Int J Endocrinol Metab"},{"issue":"6","key":"2024072410341661800_luae123-B14","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","article-title":"Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation","volume":"17","author":"Maclean","year":"2014","journal-title":"Pituitary"},{"issue":"6","key":"2024072410341661800_luae123-B15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1530\/EJE-16-0979","article-title":"Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas","volume":"176","author":"Lasolle","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2024072410341661800_luae123-B16","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00259-019-04578-z","article-title":"An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy","volume":"47","author":"Assadi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2024072410341661800_luae123-B17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/eci.12010","article-title":"ACTH-secreting Crooke cell carcinoma of the pituitary","volume":"43","author":"Kov\u00e1cs","year":"2013","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2024072410341661800_luae123-B18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/RLU.0000000000000589","article-title":"The use of 68 Ga DOTATATE PET\/CT for diagnostic assessment and monitoring of 177 Lu DOTATATE therapy in pituitary carcinoma","volume":"40","author":"Novruzov","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2024072410341661800_luae123-B19","first-page":"92","article-title":"Metastatic MEN1 syndrome treated with lutetium-177-a case report","volume":"15","author":"Gezer","year":"2019","journal-title":"Endocr Oncol"},{"issue":"1","key":"2024072410341661800_luae123-B20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11102-007-0038-6","article-title":"Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review","volume":"11","author":"Goglia","year":"2008","journal-title":"Pituitary"},{"issue":"16","key":"2024072410341661800_luae123-B21","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024072410341661800_luae123-B22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","article-title":"Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours","volume":"46","author":"van der Zwan","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2024072410341661800_luae123-B23","doi-asserted-by":"crossref","first-page":"e3507","DOI":"10.1210\/clinem\/dgaa497","article-title":"Treatment options for gonadotroph tumors: current state and perspectives","volume":"105","author":"Ilie","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024072410341661800_luae123-B24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11102-011-0370-8","article-title":"Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study","volume":"15","author":"Fusco","year":"2012","journal-title":"Pituitary"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/7\/luae123\/58625507\/luae123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/7\/luae123\/58625507\/luae123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T02:35:21Z","timestamp":1721874921000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae123\/7713614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,6,27]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae123","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,6,27]]},"article-number":"luae123"}}